Drug intelligence / Profile preview

NG-SUN

Development stage: Preclinical
Lead developer: Sun Pharma
Modality: Small Molecules

Overview

NG-SUN is a pharmaceutical product developed by Sun Pharmaceutical Industries. While specific clinical details are limited in public high-level biotech summaries, it is identified in pipeline documentation as a formulation or project related to the delivery of established active ingredients, potentially in the field of neurology or psychiatry, consistent with Sun Pharma's specialty focus. As a code name, it represents a specific investigational or proprietary formulation under development by the company.

Beyond the preview

Go deeper on NG-SUN.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NG-SUN.

Explore the full profile